Sellas Life Sciences provides corporate update

SELLAS Life Sciences Group provided a business update and will host a corporate webinar. “2023 was a very productive year for SELLAS,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “We advanced our clinical-stage programs for both galinpepimut-S and SLS009, reported positive initial topline Phase 2a data of SLS009 which showed the first complete response achieved in an acute myeloid leukemia patient resistant to venetoclax combination therapies and significant antileukemic effect and apparent survival benefit, initiated a Phase 1b/2 trial of SLS009 in relapsed/refractory peripheral T-cell lymphomas and held a successful FDA Type C meeting which solidified our GPS CMC program and commercial manufacturing and regulatory plans. We are pleased that the potential for SLS009 has been recognized by the FDA as evidenced by the granting of Fast Track Designation for PTCL and Orphan Drug Designations for AML and PTCL.”